CAR-T therapies
Feb 20, 2026
Tumor‑Infiltrating Lymphocyte (TIL) Therapies: Redefining Cell Therapy for Solid Tumors
Summary TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled, broadening options beyond PD-1 and BRAF/MEK inhibitors for metastatic melanoma, and driving extensive clinical evaluation across NSCLC, HNSCC, CRC, pancreatic, prosta...
Read More...
Feb 22, 2018
Snippet: M&A activities of big pharma’s will fuel CAR-T cell therapy
Gilead Sciences Inc. bought Kite Pharma (USD 11.9 Billion) while Celgene took over Juno Therapeutics (USD 9 Billion) to make the greatest speculation into this rising subject over the recent one year. While experts hope that each individual CAR-T therapies will yield sales of USD 1 billion, the investing companies...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
